<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Recordati S.p.A. — Co-Investment Opportunity</title>
<link href="https://fonts.googleapis.com/css2?family=EB+Garamond:ital,wght@0,400;0,500;0,600;1,400&family=DM+Sans:wght@300;400;500&display=swap" rel="stylesheet">
<script src="https://cdnjs.cloudflare.com/ajax/libs/Chart.js/4.4.1/chart.umd.js"></script>
<style>
:root {
  --navy:#0D1B3E;--nmid:#1A2F5A;--nlit:#243F78;
  --gold:#B8964E;--cream:#F8F6F1;--white:#FFFFFF;
  --g100:#F2F2F0;--g200:#E2E2DE;--g400:#A8A89E;--g600:#6C6C64;--g800:#3A3A34;
  --text:#1A1A18;--green:#1B5E42;--gl:#E8F2ED;--teal:#1A4A5A;--teall:#E6F0F4;
  --hh:110px;--tbh:52px;--top:162px;
}
*{box-sizing:border-box;margin:0;padding:0}
html{font-size:16px}
body{font-family:'DM Sans',sans-serif;font-weight:400;color:var(--text);background:var(--cream);line-height:1.7}
h1,h2,h3,h4{font-family:'EB Garamond',serif;font-weight:500;line-height:1.25}
/* HEADER */
#hdr{position:fixed;top:0;left:0;right:0;z-index:200;background:var(--navy);border-bottom:1px solid rgba(184,150,78,.25)}
.htop{display:flex;align-items:center;justify-content:space-between;padding:0 40px;height:var(--hh);gap:32px}
.brand{font-family:'EB Garamond',serif;font-size:20px;font-weight:500;color:var(--white);white-space:nowrap}
.brand span{color:var(--gold)}
.hkpis{display:flex;gap:1px;flex:1;max-width:760px;background:rgba(255,255,255,.08);border-radius:4px;overflow:hidden}
.hk{flex:1;padding:13px 16px;background:rgba(13,27,62,.6)}
.hkv{font-family:'EB Garamond',serif;font-size:21px;color:var(--white);line-height:1;margin-bottom:3px}
.hkv.g{color:var(--gold)}
.hkl{font-size:10px;color:rgba(255,255,255,.4);letter-spacing:.07em;text-transform:uppercase}
.cbadge{font-size:10px;font-weight:500;letter-spacing:.12em;text-transform:uppercase;color:var(--gold);border:1px solid rgba(184,150,78,.35);padding:5px 12px;border-radius:2px;white-space:nowrap}
/* TAB BAR */
#tabs{display:flex;align-items:stretch;border-top:1px solid rgba(255,255,255,.06);height:var(--tbh);overflow-x:auto;scrollbar-width:none}
#tabs::-webkit-scrollbar{display:none}
.tb{flex-shrink:0;padding:0 20px;font-size:12px;font-weight:400;letter-spacing:.07em;text-transform:uppercase;color:rgba(255,255,255,.5);background:transparent;border:none;cursor:pointer;border-bottom:2px solid transparent;transition:color .18s,border-color .18s;white-space:nowrap}
.tb:hover{color:rgba(255,255,255,.85)}
.tb.on{color:var(--gold);border-bottom-color:var(--gold)}
/* PANELS */
#body{padding-top:var(--top);min-height:100vh}
.panel{display:none}
.panel.on{display:block}
.pi{max-width:1100px;margin:0 auto;padding:52px 48px 72px}
/* TYPE */
.ey{font-size:11px;font-weight:500;letter-spacing:.14em;text-transform:uppercase;color:var(--gold);margin-bottom:10px}
.st{font-size:36px;color:var(--navy);margin-bottom:8px}
.ss{font-size:16px;color:var(--g600);margin-bottom:36px;max-width:620px;line-height:1.65}
.dv{width:36px;height:2px;background:var(--gold);margin-bottom:28px}
/* THESIS */
.tgrid{display:grid;grid-template-columns:repeat(3,1fr);gap:20px}
.tc{background:var(--white);border:1px solid var(--g200);border-top:3px solid var(--gold);border-radius:6px;padding:26px 22px;transition:box-shadow .2s}
.tc:hover{box-shadow:0 6px 24px rgba(0,0,0,.07)}
.tn{font-family:'EB Garamond',serif;font-size:36px;color:var(--g200);line-height:1;margin-bottom:10px}
.tc h3{font-size:16px;color:var(--navy);margin-bottom:8px}
.tc p{font-size:13.5px;color:var(--g600);line-height:1.6}
/* KPI ROW */
.kr{display:grid;grid-template-columns:repeat(5,1fr);gap:1px;background:var(--g200);border:1px solid var(--g200);border-radius:6px;overflow:hidden;margin-bottom:36px}
.kp{background:var(--white);padding:20px 18px}
.kv{font-family:'EB Garamond',serif;font-size:26px;color:var(--navy);line-height:1;margin-bottom:3px}
.kd{font-size:12px;color:var(--green);font-weight:500;margin-bottom:4px}
.kl{font-size:11.5px;color:var(--g600)}
/* CHARTS */
.cgrid{display:grid;grid-template-columns:1fr 1fr;gap:28px}
.cc{background:var(--white);border:1px solid var(--g200);border-radius:6px;padding:24px}
.ct{font-family:'EB Garamond',serif;font-size:18px;color:var(--navy);margin-bottom:3px}
.cs{font-size:12px;color:var(--g400);margin-bottom:16px}
.cw{position:relative;height:220px}
.leg{display:flex;gap:16px;margin-top:10px;font-size:12px;color:var(--g600);flex-wrap:wrap}
.ld{width:10px;height:10px;border-radius:2px;display:inline-block;flex-shrink:0}
.ll{width:18px;height:2px;display:inline-block;flex-shrink:0;margin-bottom:2px;vertical-align:middle}
/* GUIDANCE */
.gg{display:grid;grid-template-columns:repeat(3,1fr);gap:16px;margin-top:24px}
.gc{background:var(--g100);padding:18px 16px;border-radius:6px}
.gcl{font-size:11px;color:var(--g600);letter-spacing:.07em;text-transform:uppercase;margin-bottom:8px}
.gcv{font-family:'EB Garamond',serif;font-size:22px;color:var(--navy)}
.gcn{font-size:12px;color:var(--green);margin-top:4px}
/* CAP TABLE */
.capw{display:grid;grid-template-columns:1fr 1.15fr;gap:48px;align-items:start}
.capch{position:relative;height:300px}
.capleg{margin-top:16px;display:flex;flex-direction:column;gap:9px}
.capn{margin-top:16px;padding:14px 16px;background:var(--teall);border-left:3px solid var(--teal);border-radius:4px}
.capnt{font-size:12px;font-weight:500;color:var(--teal);margin-bottom:4px}
.capnd{font-size:12.5px;color:var(--g600);line-height:1.6}
/* TABLES */
table.s{width:100%;border-collapse:collapse;font-size:13.5px}
table.s th{text-align:left;padding:9px 12px;font-size:11px;font-weight:500;letter-spacing:.07em;text-transform:uppercase;color:var(--g600);border-bottom:2px solid var(--navy)}
table.s td{padding:10px 12px;border-bottom:1px solid var(--g200);color:var(--text);vertical-align:middle}
table.s tr:last-child td{border-bottom:none}
table.s tr.tr td{font-weight:500;color:var(--navy);border-top:2px solid var(--navy);background:var(--g100)}
.bx{display:inline-block;font-size:10px;font-weight:500;padding:2px 8px;border-radius:2px;letter-spacing:.05em;text-transform:uppercase}
.bl{background:var(--navy);color:#fff}
.bc{background:var(--gl);color:var(--green)}
.bf{background:var(--g100);color:var(--g600)}
.bp{background:#FEF3E2;color:#9A5B0A}
.bm{background:var(--gl);color:var(--green)}
/* DEAL */
.dgrid{display:grid;grid-template-columns:1fr 1.2fr;gap:40px;align-items:start}
.dsumm{background:var(--navy);border-radius:8px;padding:28px 24px;color:var(--white)}
.dst{font-family:'EB Garamond',serif;font-size:18px;color:var(--gold);margin-bottom:20px}
.dsr{display:flex;justify-content:space-between;align-items:center;padding:10px 0;border-bottom:1px solid rgba(255,255,255,.09);font-size:13.5px}
.dsr:last-child{border-bottom:none}
.dsl{color:rgba(255,255,255,.55)}
.dsv{font-weight:500;color:var(--white)}
.dsv.g{color:var(--gold)}
.dsv.gr{color:#6BCFAA}
.steps{margin-top:24px;display:flex;flex-direction:column;gap:16px}
.step{display:flex;gap:14px;align-items:flex-start}
.sn{width:28px;height:28px;border-radius:50%;background:var(--navy);color:var(--gold);display:flex;align-items:center;justify-content:center;font-size:13px;font-weight:500;flex-shrink:0;margin-top:2px}
.step h4{font-size:14px;color:var(--navy);margin-bottom:2px}
.step p{font-size:13px;color:var(--g600)}
.sotpl{font-size:12px;font-weight:500;letter-spacing:.06em;text-transform:uppercase;color:var(--g600);margin-bottom:10px}
.sotpn{font-size:11.5px;color:var(--g400);font-style:italic;margin-top:10px;line-height:1.5}
/* MARKET */
.mkpi{display:grid;grid-template-columns:repeat(4,1fr);gap:1px;background:var(--g200);border:1px solid var(--g200);border-radius:6px;overflow:hidden;margin-bottom:32px}
.mk{background:var(--navy);padding:20px 16px}
.mkl{font-size:10px;letter-spacing:.07em;text-transform:uppercase;color:rgba(255,255,255,.4);margin-bottom:7px}
.mkv{font-family:'EB Garamond',serif;font-size:26px;color:var(--white);line-height:1}
.mkn{font-size:11.5px;color:var(--gold);margin-top:4px}
/* DRUG TABLE */
.drug-grid{display:grid;grid-template-columns:1fr 1fr;gap:28px;margin-bottom:32px}
.drug-table-card{background:var(--white);border:1px solid var(--g200);border-radius:6px;overflow:hidden}
.drug-table-header{background:var(--navy);padding:14px 18px}
.drug-table-header h3{font-family:'EB Garamond',serif;font-size:18px;color:var(--white);margin-bottom:2px}
.drug-table-header p{font-size:12px;color:rgba(255,255,255,.5)}
.drug-row{display:grid;grid-template-columns:1fr 1fr 120px;gap:0;border-bottom:1px solid var(--g200)}
.drug-row:last-child{border-bottom:none}
.drug-row>div{padding:10px 16px;font-size:13px}
.drug-row>div:first-child{font-weight:500;color:var(--navy);border-right:1px solid var(--g200)}
.drug-row>div:nth-child(2){color:var(--g600);font-size:12.5px;border-right:1px solid var(--g200)}
.drug-row>div:last-child{color:var(--g600);font-size:11.5px;text-align:center;display:flex;align-items:center;justify-content:center}
.drug-col-hdr{background:var(--g100);display:grid;grid-template-columns:1fr 1fr 120px;gap:0}
.drug-col-hdr>span{padding:8px 16px;font-size:10px;font-weight:500;letter-spacing:.07em;text-transform:uppercase;color:var(--g600);border-bottom:2px solid var(--navy)}
.drug-col-hdr>span:first-child{border-right:1px solid var(--g200)}
.drug-col-hdr>span:nth-child(2){border-right:1px solid var(--g200)}
.pipeline-stats{display:grid;grid-template-columns:repeat(3,1fr);gap:12px;margin-top:20px}
.psc{text-align:center;padding:14px;background:var(--g100);border-radius:6px}
.psv{font-family:'EB Garamond',serif;font-size:24px;color:var(--navy)}
.psl{font-size:11px;color:var(--g400)}
/* CO-INVESTORS */
.ittl{font-size:12px;font-weight:500;letter-spacing:.07em;text-transform:uppercase;color:var(--g400);margin:28px 0 12px;padding-bottom:7px;border-bottom:1px solid var(--g200)}
.ir{display:grid;grid-template-columns:200px 90px 1fr 90px;gap:14px;align-items:center;padding:12px 0;border-bottom:1px solid var(--g200);font-size:13px}
.ir:last-child{border-bottom:none}
.in{font-weight:500;color:var(--navy)}
.it{font-size:11px;color:var(--g400);margin-top:2px}
.ia{font-size:13px;font-weight:500;color:var(--g800)}
.ino{font-size:12px;color:var(--g600);line-height:1.5}
.fp{display:inline-block;font-size:10px;font-weight:500;padding:3px 10px;border-radius:10px;text-transform:uppercase;letter-spacing:.05em}
.fs{background:var(--gl);color:var(--green)}
.fm{background:#FEF3E2;color:#9A5B0A}
/* RETURNS */
.rgrid{display:grid;grid-template-columns:repeat(3,1fr);gap:20px;margin-bottom:28px}
.sc{border:1px solid var(--g200);border-radius:8px;overflow:hidden}
.sch{padding:16px 20px;display:flex;justify-content:space-between;align-items:center}
.sch h3{font-size:18px;color:var(--white)}
.sct{font-size:11px;font-weight:500;letter-spacing:.06em;text-transform:uppercase;color:rgba(255,255,255,.65)}
.bear .sch{background:#3A2020}
.base .sch{background:var(--navy)}
.bull .sch{background:var(--green)}
.scb{padding:16px 20px}
.ss2{display:flex;justify-content:space-between;padding:7px 0;border-bottom:1px solid var(--g200);font-size:13px}
.ss2:last-child{border-bottom:none}
.ssl{color:var(--g600)}
.ssv{font-weight:500;color:var(--navy)}
.ssv.hi{color:var(--green);font-family:'EB Garamond',serif;font-size:16px}
.rd{font-size:12px;color:var(--g400);font-style:italic;margin-top:8px;line-height:1.5}
/* RISKS */
.rg{display:grid;grid-template-columns:1fr 1fr;gap:18px}
.rc{border:1px solid var(--g200);border-radius:6px;padding:20px;border-left:4px solid var(--g400)}
.rc.high{border-left-color:#C0392B}
.rc.med{border-left-color:#E67E22}
.rc.low{border-left-color:var(--green)}
.rh{display:flex;justify-content:space-between;align-items:flex-start;margin-bottom:9px}
.rt{font-family:'EB Garamond',serif;font-size:17px;color:var(--navy)}
.rl{font-size:10px;font-weight:500;letter-spacing:.07em;text-transform:uppercase;padding:3px 9px;border-radius:2px}
.rhi{background:#FDEDEC;color:#C0392B}
.rme{background:#FEF9E7;color:#9A5B0A}
.rlo{background:var(--gl);color:var(--green)}
.rdesc{font-size:13px;color:var(--g600);line-height:1.6;margin-bottom:9px}
.rmit{font-size:12px;color:var(--teal);font-weight:500}
/* SPACING */
.mt16{margin-top:16px}.mt24{margin-top:24px}.mt28{margin-top:28px}.mt32{margin-top:32px}
/* FOOTER */
footer{background:var(--navy);padding:28px 48px;display:flex;justify-content:space-between;align-items:center;gap:40px}
.fb{font-family:'EB Garamond',serif;font-size:16px;color:var(--white);white-space:nowrap}
.fb span{color:var(--gold)}
.fd{font-size:11px;color:rgba(255,255,255,.3);max-width:640px;line-height:1.6}
@media(max-width:860px){
  .tgrid,.cgrid,.dgrid,.rg,.capw,.drug-grid{grid-template-columns:1fr}
  .kr,.mkpi{grid-template-columns:repeat(2,1fr)}
  .ir{grid-template-columns:1fr 1fr}
  .rgrid{grid-template-columns:1fr}
  .hkpis{display:none}
  .pi{padding:36px 24px 60px}
}
</style>
</head>
<body>

<div id="hdr">
  <div class="htop">
    <div class="brand">Recordati <span>S.p.A.</span></div>
    <div class="hkpis">
      <div class="hk"><div class="hkv g">€10.11bn</div><div class="hkl">Enterprise Value</div></div>
      <div class="hk"><div class="hkv">€52.00</div><div class="hkl">Offer Price per Share</div></div>
      <div class="hk"><div class="hkv">€2,618M</div><div class="hkl">FY2025 Revenue</div></div>
      <div class="hk"><div class="hkv g">€991M</div><div class="hkl">FY2025 EBITDA</div></div>
      <div class="hk"><div class="hkv">10.2×</div><div class="hkl">EV / EBITDA Entry</div></div>
    </div>
    <div class="cbadge">Confidential</div>
  </div>
  <div id="tabs">
    <button class="tb on" data-tab="thesis">Investment Thesis</button>
    <button class="tb" data-tab="financials">Financials</button>
    <button class="tb" data-tab="captable">Cap Table</button>
    <button class="tb" data-tab="deal">Deal Structure</button>
    <button class="tb" data-tab="market">Market</button>
    <button class="tb" data-tab="coinvestors">Co-Investors</button>
    <button class="tb" data-tab="returns">Returns</button>
    <button class="tb" data-tab="risks">Risk Factors</button>
  </div>
</div>

<div id="body">

<!-- THESIS -->
<div class="panel on" id="p-thesis">
  <div class="pi">
    <div class="ey">Co-Investment Opportunity · April 2026</div>
    <h2 class="st">Why Recordati, Why Now</h2>
    <div class="dv"></div>
    <p class="ss">Recordati is a global pharmaceutical company with commercial operations across more than 150 countries. A transaction at €10.11bn enterprise value presents a rare opportunity to co-invest alongside a proven sponsor in a high-quality rare disease drugs and specialty pharma platform. The take-private creates the conditions to realise embedded value that the public market has not fully priced.</p>
    <div class="tgrid">
      <div class="tc"><div class="tn">01</div><h3>Rare Disease Drugs Scarcity Premium</h3><p>Recordati markets 11 rare disease drugs with strong patent protection. Isturisa alone is on track for peak sales above €1.2bn. Rare disease drugs command 18 to 22 times EBITDA compared to 9 to 11 times for specialty pharma, creating a structural valuation gap that exists at the group level today.</p></div>
      <div class="tc"><div class="tn">02</div><h3>Carve-out Value Unlock</h3><p>Following the take-private, the rare disease division can be separated and sold to a strategic buyer at premium multiples. Proceeds from that sale alone, estimated at €8.6bn to €10.5bn, are sufficient to recover the full acquisition cost of the transaction.</p></div>
      <div class="tc"><div class="tn">03</div><h3>Specialty Pharma Cash Engine</h3><p>The specialty pharma business generates €1.48bn in revenue and produces €559M in annual free cash flow. This steady income stream covers debt service throughout the hold period while the rare disease division is prepared for a premium exit.</p></div>
      <div class="tc"><div class="tn">04</div><h3>Pipeline and Label Optionality</h3><p>A Moderna mRNA partnership signed in January 2026, the Enjaymo acquisition from Sanofi for $825M, and an FDA label expansion for Isturisa in April 2025 represent meaningful upside that is not yet reflected in the entry valuation of 10.2 times EBITDA.</p></div>
      <div class="tc"><div class="tn">05</div><h3>Long-Duration Capital Fit</h3><p>This is a 3 to 5 year strategic reshape. Patient capital earns a structurally better return by holding through the specialty pharma cash accumulation phase and timing the rare disease division exit to peak valuations.</p></div>
      <div class="tc"><div class="tn">06</div><h3>Sponsor Continuity Since 2018</h3><p>CVC has owned Recordati since 2018 through the Rossini HoldCo structure alongside PSP Investments, StepStone and AlpInvest. Deep management relationships exist, operational familiarity is proven and there is no integration risk — only value realisation.</p></div>
    </div>
  </div>
</div>

<!-- FINANCIALS -->
<div class="panel" id="p-financials">
  <div class="pi">
    <div class="ey">Financial Performance</div>
    <h2 class="st">Consistent Compounding</h2>
    <div class="dv"></div>
    <div class="kr">
      <div class="kp"><div class="kv">€2,618M</div><div class="kd">+11.8%</div><div class="kl">FY2025 Revenue</div></div>
      <div class="kp"><div class="kv">€991M</div><div class="kd">+14.5%</div><div class="kl">FY2025 EBITDA</div></div>
      <div class="kp"><div class="kv">37.8%</div><div class="kd">+90bps</div><div class="kl">EBITDA Margin</div></div>
      <div class="kp"><div class="kv">€559M</div><div class="kd">+8.2%</div><div class="kl">Free Cash Flow</div></div>
      <div class="kp"><div class="kv">2.1×</div><div class="kd">Pre-deal</div><div class="kl">Net Debt / EBITDA</div></div>
    </div>
    <div class="cgrid">
      <div class="cc">
        <div class="ct">Revenue by Division</div>
        <div class="cs">FY2021 to FY2025 · €M · Rare Disease division grew 29.7% in FY2025</div>
        <div class="cw"><canvas id="revChart" role="img" aria-label="Recordati revenue by division 2021 to 2025"></canvas></div>
        <div class="leg mt16">
          <span style="display:flex;align-items:center;gap:6px;"><span class="ld" style="background:#0D1B3E;"></span>Rare Disease</span>
          <span style="display:flex;align-items:center;gap:6px;"><span class="ld" style="background:#B8964E;"></span>Specialty Pharma</span>
        </div>
      </div>
      <div class="cc">
        <div class="ct">EBITDA and Margin Trend</div>
        <div class="cs">FY2021 to FY2025 · €M and % · Consistent margin expansion across five years</div>
        <div class="cw"><canvas id="ebitdaChart" role="img" aria-label="Recordati EBITDA and margin 2021 to 2025"></canvas></div>
        <div class="leg mt16">
          <span style="display:flex;align-items:center;gap:6px;"><span class="ld" style="background:#0D1B3E;"></span>EBITDA €M</span>
          <span style="display:flex;align-items:center;gap:6px;"><span class="ll" style="background:#B8964E;"></span>Margin %</span>
        </div>
      </div>
    </div>
    <div class="cc mt24">
      <div class="ct">FY2026 Management Guidance</div>
      <div class="cs">Issued February 17, 2026 alongside confirmed FY2025 preliminary results. FX headwind of approximately 3.5% included in guidance range.</div>
      <div class="gg">
        <div class="gc"><div class="gcl">Revenue</div><div class="gcv">€2,730 to 2,800M</div><div class="gcn">+4.3% to +6.9% year on year</div></div>
        <div class="gc"><div class="gcl">EBITDA</div><div class="gcv">€995 to 1,030M</div><div class="gcn">Midpoint €1,013M · Forward EV/EBITDA 10.0×</div></div>
        <div class="gc"><div class="gcl">Adjusted Net Income</div><div class="gcv">€655 to 685M</div><div class="gcn">Margin ~24.0%</div></div>
      </div>
    </div>
  </div>
</div>

<!-- CAP TABLE -->
<div class="panel" id="p-captable">
  <div class="pi">
    <div class="ey">Capital Structure</div>
    <h2 class="st">Current Cap Table</h2>
    <div class="dv"></div>
    <p class="ss">As of 10th April 2026. CVC controls 46.8% through the Rossini HoldCo alongside existing co-investors. The free float represents the shares to be acquired in the take-private offer.</p>
    <div class="capw">
      <div>
        <div class="capch"><canvas id="capChart" role="img" aria-label="Recordati ownership breakdown"></canvas></div>
        <div class="capleg" id="capLeg"></div>
      </div>
      <div>
        <h3 style="font-size:18px;color:var(--navy);margin-bottom:18px;">Shareholder Detail</h3>
        <table class="s">
          <thead><tr><th>Shareholder</th><th>Stake</th><th>Vehicle</th><th>Type</th></tr></thead>
          <tbody>
            <tr><td><strong>CVC Capital Partners</strong><br><span style="font-size:11.5px;color:var(--g400);">Lead sponsor</span></td><td><strong>~31.5%</strong></td><td style="font-size:12px;color:var(--g600);">Rossini HoldCo (Lux)</td><td><span class="bx bl">Lead</span></td></tr>
            <tr><td><strong>PSP Investments</strong><br><span style="font-size:11.5px;color:var(--g400);">Canadian PPF · C$264bn AUM</span></td><td><strong>~6.0%</strong></td><td style="font-size:12px;color:var(--g600);">Via Rossini HoldCo</td><td><span class="bx bc">Existing Co-investor</span></td></tr>
            <tr><td><strong>StepStone Group</strong><br><span style="font-size:11.5px;color:var(--g400);">PE co-investment platform · $700bn AUM</span></td><td><strong>~5.5%</strong></td><td style="font-size:12px;color:var(--g600);">Via Rossini HoldCo</td><td><span class="bx bc">Existing Co-investor</span></td></tr>
            <tr><td><strong>AlpInvest Partners</strong><br><span style="font-size:11.5px;color:var(--g400);">Carlyle subsidiary · ~$100bn AUM</span></td><td><strong>~3.8%</strong></td><td style="font-size:12px;color:var(--g600);">Via Rossini HoldCo</td><td><span class="bx bc">Existing Co-investor</span></td></tr>
            <tr><td><strong>Free Float</strong><br><span style="font-size:11.5px;color:var(--g400);">Borsa Italiana (MIL: REC)</span></td><td><strong>~53.2%</strong></td><td style="font-size:12px;color:var(--g600);">Public market</td><td><span class="bx bf">Public Float</span></td></tr>
            <tr class="tr"><td><strong>Total</strong></td><td><strong>100%</strong></td><td></td><td></td></tr>
          </tbody>
        </table>
        <div class="capn mt16">
          <div class="capnt">Note on Rossini HoldCo</div>
          <div class="capnd">CVC, PSP, StepStone and AlpInvest hold their combined 46.8% stake through Rossini HoldCo S.à r.l., incorporated in Luxembourg. The take-private offer targets the remaining 53.2% free float at €52 per share, representing a ~6.5% premium to the last closing price of €48.84 on 10th April 2026.</div>
        </div>
      </div>
    </div>
  </div>
</div>

<!-- DEAL STRUCTURE -->
<div class="panel" id="p-deal">
  <div class="pi">
    <div class="ey">Transaction</div>
    <h2 class="st">Deal Structure and Rationale</h2>
    <div class="dv"></div>
    <div class="dgrid">
      <div>
        <div class="dsumm">
          <div class="dst">Transaction Summary</div>
          <div class="dsr"><span class="dsl">Offer price</span><span class="dsv g">€52.00 per share</span></div>
          <div class="dsr"><span class="dsl">Last closing price</span><span class="dsv">€48.84 (10 Apr 2026)</span></div>
          <div class="dsr"><span class="dsl">Premium to last close</span><span class="dsv">~6.5%</span></div>
          <div class="dsr"><span class="dsl">Market capitalisation</span><span class="dsv g">€10.11bn</span></div>
          <div class="dsr"><span class="dsl">Enterprise Value</span><span class="dsv g">€10.11bn</span></div>
          <div class="dsr"><span class="dsl">Entry EV / FY2025 EBITDA</span><span class="dsv">10.2× (€991M)</span></div>
          <div class="dsr"><span class="dsl">Forward EV / FY2026 EBITDA</span><span class="dsv">10.0× (midpoint €1,013M)</span></div>
          <div class="dsr"><span class="dsl">Total equity required</span><span class="dsv">€5.5 to 6.0bn</span></div>
          <div class="dsr"><span class="dsl">Implied leverage</span><span class="dsv">~7.0 to 7.5× EBITDA</span></div>
          <div class="dsr"><span class="dsr"><span class="dsl">Expected close</span><span class="dsv">H2 2026</span></div>
          <div class="dsr"><span class="dsl">Target exit IRR</span><span class="dsv gr">25 to 45%</span></div>
        </div>
        <div class="steps mt24">
          <div class="step"><div class="sn">1</div><div><h4>Mandatory tender offer</h4><p>CVC launches a public tender offer for 100% of Recordati shares at €52 per share. Existing Rossini partners commit to rolling their 15.3% stake into the new private structure.</p></div></div>
          <div class="step"><div class="sn">2</div><div><h4>Co-investor consortium formation</h4><p>New equity capital of €3 to 4bn is required from co-investors. CVC is in active discussions with ADIA, GIC, CDPQ and GBL. Typical ticket size ranges from €300M to €1.5bn per investor.</p></div></div>
          <div class="step"><div class="sn">3</div><div><h4>Rare disease division sale in Year 2 to 3</h4><p>Following delisting, the rare disease division operates as an independent subsidiary. A strategic sale or IPO is targeted at 18 to 22 times EBITDA. Proceeds of €8.6bn to €10.5bn can repay substantially all acquisition debt.</p></div></div>
        </div>
      </div>
      <div>
        <div class="sotpl">Sum-of-the-parts value bridge</div>
        <div class="cc">
          <div class="ct">SOTP Valuation vs Entry Price</div>
          <div class="cs">Entry at €10.11bn · Estimated SOTP range €12.2 to 15.0bn · Values in €bn</div>
          <div class="cw" style="height:240px;"><canvas id="sotpChart" role="img" aria-label="SOTP valuation bar chart"></canvas></div>
        </div>
        <div class="mt24">
          <table class="s">
            <thead><tr><th>Division</th><th>Revenue</th><th>Est. EBITDA</th><th>Multiple</th><th>Value</th></tr></thead>
            <tbody>
              <tr><td><strong>Rare Disease (RRD)</strong></td><td>€1,141M</td><td>~€435M</td><td>18 to 22×</td><td><strong>€7.8 to 9.6bn</strong></td></tr>
              <tr><td><strong>Specialty Pharma (SPC)</strong></td><td>€1,478M</td><td>~€490M</td><td>9 to 11×</td><td><strong>€4.4 to 5.4bn</strong></td></tr>
              <tr class="tr"><td><strong>SOTP Total</strong></td><td>€2,619M</td><td>~€925M</td><td></td><td><strong>€12.2 to 15.0bn</strong></td></tr>
            </tbody>
          </table>
          <p class="sotpn mt16">Note: EBITDA estimates are illustrative allocations based on an assumed rare disease margin of 38 to 40% versus a blended group margin of 37.8%. All figures are for indicative purposes only and do not constitute financial projections.</p>
        </div>
      </div>
    </div>
  </div>
</div>

<!-- MARKET -->
<div class="panel" id="p-market">
  <div class="pi">
    <div class="ey">Rare Disease Market</div>
    <h2 class="st">Structural Tailwinds</h2>
    <div class="dv"></div>
    <div class="mkpi">
      <div class="mk"><div class="mkl">Global Rare Disease Market 2024</div><div class="mkv">$154.6bn</div><div class="mkn">Projected $495bn by 2033</div></div>
      <div class="mk"><div class="mkl">Market CAGR 2024 to 2033</div><div class="mkv">13.8%</div><div class="mkn">DataM Intelligence 2024</div></div>
      <div class="mk"><div class="mkl">Recordati Rare Disease YoY</div><div class="mkv">+29.7%</div><div class="mkn">FY2025 vs FY2024</div></div>
      <div class="mk"><div class="mkl">Average Diagnosis Delay</div><div class="mkv">4 to 5 yrs</div><div class="mkn">Persistent unmet demand</div></div>
    </div>

    <div class="cgrid mt16">
      <div class="cc">
        <div class="ct">Global Rare Disease Market Growth</div>
        <div class="cs">2023 to 2033E · $bn · CAGR of 13.8%</div>
        <div class="cw"><canvas id="marketChart" role="img" aria-label="Global rare disease market 2023 to 2033"></canvas></div>
      </div>
      <div>
        <div class="pipeline-stats" style="grid-template-columns:repeat(3,1fr);">
          <div class="psc"><div class="psv">11</div><div class="psl">US Patents</div></div>
          <div class="psc"><div class="psv">284</div><div class="psl">Patent Families</div></div>
          <div class="psc"><div class="psv">98</div><div class="psl">Countries</div></div>
        </div>
        <div class="mt16" style="font-size:12px;font-weight:500;letter-spacing:.07em;text-transform:uppercase;color:var(--g600);margin-bottom:10px;">Rare Disease Drug Portfolio — 11 Marketed Products</div>
        <div class="drug-table-card">
          <div class="drug-col-hdr">
            <span>Drug (Brand Name)</span>
            <span>Indication</span>
            <span style="text-align:center;">Therapeutic Area</span>
          </div>
          <div class="drug-row"><div>Isturisa® (osilodrostat)</div><div>Cushing's Syndrome</div><div><span class="bx bm">Endocrinology</span></div></div>
          <div class="drug-row"><div>Signifor® (pasireotide)</div><div>Cushing's Disease / Acromegaly</div><div><span class="bx bm">Endocrinology</span></div></div>
          <div class="drug-row"><div>Signifor® LAR (pasireotide)</div><div>Acromegaly</div><div><span class="bx bm">Endocrinology</span></div></div>
          <div class="drug-row"><div>Enjaymo® (sutimlimab)</div><div>Cold Agglutinin Disease</div><div><span class="bx" style="background:#EEF0FE;color:#3C3489;">Haematology</span></div></div>
          <div class="drug-row"><div>Sylvant® (siltuximab)</div><div>Castleman Disease (iMCD)</div><div><span class="bx bp">Oncology</span></div></div>
          <div class="drug-row"><div>Qarziba® (dinutuximab beta)</div><div>High-Risk Neuroblastoma</div><div><span class="bx bp">Oncology</span></div></div>
          <div class="drug-row"><div>Panhematin® (hemin)</div><div>Acute Porphyria (US)</div><div><span class="bx" style="background:#F1EFE8;color:#444441;">Metabolism</span></div></div>
          <div class="drug-row"><div>Normosang® (heme arginate)</div><div>Acute Porphyria (Europe)</div><div><span class="bx" style="background:#F1EFE8;color:#444441;">Metabolism</span></div></div>
          <div class="drug-row"><div>Carbaglu® (carglumic acid)</div><div>NAGS Deficiency / Organic Acidemia</div><div><span class="bx" style="background:#F1EFE8;color:#444441;">Metabolism</span></div></div>
          <div class="drug-row"><div>Cystadane® (betaine anhydrous)</div><div>Homocystinuria</div><div><span class="bx" style="background:#F1EFE8;color:#444441;">Metabolism</span></div></div>
          <div class="drug-row"><div>Cystadrops® (cysteamine)</div><div>Cystinosis (corneal crystals)</div><div><span class="bx" style="background:#F1EFE8;color:#444441;">Metabolism</span></div></div>
        </div>
        <div style="margin-top:10px;font-size:11.5px;color:var(--g400);font-style:italic;">Sources: Recordati Rare Diseases product pages (medical.recordatirarediseases.com and recordatirarediseases.com) · April 2025</div>
      </div>
    </div>

    <div class="cc mt24">
      <div class="ct">Pipeline</div>
      <div class="cs">Key development-stage and recently approved assets</div>
      <table class="s">
        <thead><tr><th>Asset</th><th>Partner</th><th>Indication</th><th>Stage</th><th>Note</th></tr></thead>
        <tbody>
          <tr><td><strong>mRNA-3927</strong></td><td>Moderna</td><td>Propionic Acidemia</td><td><span class="bx bp">Phase 3</span></td><td style="font-size:12px;color:var(--g600);">Partnership signed Jan 2026</td></tr>
          <tr><td><strong>Isturisa® label expansion</strong></td><td>In-house</td><td>All Cushing's Syndrome</td><td><span class="bx bm">Approved</span></td><td style="font-size:12px;color:var(--g600);">FDA label expanded Apr 2025</td></tr>
          <tr><td><strong>Enjaymo®</strong></td><td>Acquired from Sanofi</td><td>Cold Agglutinin Disease</td><td><span class="bx bm">Commercial</span></td><td style="font-size:12px;color:var(--g600);">$825M acquisition, 2024</td></tr>
        </tbody>
      </table>
    </div>
  </div>
</div>

<!-- CO-INVESTORS -->
<div class="panel" id="p-coinvestors">
  <div class="pi">
    <div class="ey">Co-Investor Universe</div>
    <h2 class="st">Who Should Be in This Deal</h2>
    <div class="dv"></div>
    <p class="ss">Selected investors across private equity firms, sovereign wealth funds, pension funds and strategic holding companies.</p>

    <div class="ittl">Tier 1 — Existing Rossini HoldCo Partners (Roll-forward candidates)</div>
    <div class="ir" style="font-size:11px;color:var(--g400);font-weight:500;padding:6px 0;border-bottom:2px solid var(--g200);"><span>Investor</span><span>AUM</span><span>Rationale</span><span>Status</span></div>
    <div class="ir"><div><div class="in">PSP Investments</div><div class="it">Canadian Public Pension</div></div><div class="ia">C$264bn</div><div class="ino">Original 2018 consortium member. Zero diligence required. Rolling existing stake into the new structure.</div><div><span class="fp fs">Priority</span></div></div>
    <div class="ir"><div><div class="in">StepStone Group</div><div class="it">PE Co-Investment Platform</div></div><div class="ia">$700bn</div><div class="ino">Co-investment specialist in original 2018 deal. Natural candidate to re-up at the take-private.</div><div><span class="fp fs">Priority</span></div></div>
    <div class="ir"><div><div class="in">AlpInvest Partners</div><div class="it">Carlyle Subsidiary</div></div><div class="ia">~$100bn</div><div class="ino">Co-investor via Rossini since 2018. Secondaries and co-investment mandate. CVC will approach first.</div><div><span class="fp fs">Priority</span></div></div>

    <div class="ittl">Tier 2 — Confirmed in Active CVC Discussions (Bloomberg, April 2026)</div>
    <div class="ir"><div><div class="in">ADIA</div><div class="it">Abu Dhabi SWF</div></div><div class="ia">~$1.1tn</div><div class="ino">Co-invested 26% in Dechra pharma take-private (2023). Co-invested in Hologic with Blackstone and TPG (2025). Programmatic healthcare P2P co-investor.</div><div><span class="fp fs">In Talks</span></div></div>
    <div class="ir"><div><div class="in">GIC</div><div class="it">Singapore SWF</div></div><div class="ia">~$800bn</div><div class="ino">Invested in Cimed pharma (2025). Co-invested in Hologic alongside ADIA (2025). Targets a 20 year investment horizon.</div><div><span class="fp fs">In Talks</span></div></div>
    <div class="ir"><div><div class="in">CDPQ (La Caisse)</div><div class="it">Quebec Pension Fund</div></div><div class="ia">C$517bn</div><div class="ino">PE returned 17.2% in 2024. Paris office active in European transactions. Targets C$20bn in PE deployment per year.</div><div><span class="fp fs">In Talks</span></div></div>
    <div class="ir"><div><div class="in">GBL</div><div class="it">Belgian Holding Co.</div></div><div class="ia">NAV €14bn</div><div class="ino">Healthcare platforms drove €584M NAV growth in 2025. LTV at 0% gives full balance sheet capacity. Reinvesting €3bn into private assets by 2027.</div><div><span class="fp fs">In Talks</span></div></div>

    <div class="ittl">Tier 3 — PE Co-Investors with Large-Cap Healthcare Buyout Mandate</div>
    <div class="ir"><div><div class="in">EQT</div><div class="it">Swedish PE · EQT X (€22bn)</div></div><div class="ia">€22bn fund</div><div class="ino">Healthcare is EQT's primary theme. Dechra pharma take-private (2023) is a direct precedent. EQT X announced 4 take-privates in Year 1 of deployment.</div><div><span class="fp fs">Strong</span></div></div>
    <div class="ir"><div><div class="in">Cinven</div><div class="it">European PE · Fund 8 ($14.5bn)</div></div><div class="ia">$14.5bn fund</div><div class="ino">Deepest European pharma buyout track record. STADA, Medpace and AMCo are direct Recordati comparables. Healthcare is a core sector.</div><div><span class="fp fs">Strong</span></div></div>
    <div class="ir"><div><div class="in">Bain Capital</div><div class="it">PE · Europe VI + Fund XIV</div></div><div class="ia">€6bn + $14bn</div><div class="ino">Healthcare is one of five core verticals. Co-owner of STADA. Europe Fund VI (Oct 2023) dedicated to European buyouts in scope.</div><div><span class="fp fs">Strong</span></div></div>
    <div class="ir"><div><div class="in">Advent International</div><div class="it">PE · GPE XI (~$26bn target)</div></div><div class="ia">~$26bn</div><div class="ino">Healthcare is one of five core sectors. More than 25 P2P transactions and more than 90 corporate carve-outs globally. Italy is a key market.</div><div><span class="fp fm">Approach</span></div></div>
  </div>
</div>

<!-- RETURNS -->
<div class="panel" id="p-returns">
  <div class="pi">
    <div class="ey">Returns Analysis</div>
    <h2 class="st">Illustrative Return Scenarios</h2>
    <div class="dv"></div>
    <p class="ss">All figures are illustrative only and do not constitute financial projections. Based on a 2 to 3 year hold period, a rare disease division exit at varying EBITDA multiples and retention of the specialty pharma business throughout.</p>
    <div class="rgrid">
      <div class="sc bear">
        <div class="sch"><h3>Bear Case</h3><span class="sct">15× RRD EBITDA</span></div>
        <div class="scb">
          <div class="ss2"><span class="ssl">RRD Exit Multiple</span><span class="ssv">15× EBITDA</span></div>
          <div class="ss2"><span class="ssl">RRD Proceeds</span><span class="ssv">~€6.5bn</span></div>
          <div class="ss2"><span class="ssl">SPC Value</span><span class="ssv">~€4.4bn</span></div>
          <div class="ss2"><span class="ssl">SOTP Value</span><span class="ssv">~€10.9bn</span></div>
          <div class="ss2"><span class="ssl">Estimated MOIC</span><span class="ssv hi">~1.3 to 1.5×</span></div>
          <div class="ss2"><span class="ssl">Estimated IRR</span><span class="ssv">~15 to 20%</span></div>
        </div>
      </div>
      <div class="sc base">
        <div class="sch"><h3>Base Case</h3><span class="sct">18× RRD EBITDA</span></div>
        <div class="scb">
          <div class="ss2"><span class="ssl">RRD Exit Multiple</span><span class="ssv">18× EBITDA</span></div>
          <div class="ss2"><span class="ssl">RRD Proceeds</span><span class="ssv">~€7.8bn</span></div>
          <div class="ss2"><span class="ssl">SPC Value</span><span class="ssv">~€4.8bn</span></div>
          <div class="ss2"><span class="ssl">SOTP Value</span><span class="ssv">~€12.6bn</span></div>
          <div class="ss2"><span class="ssl">Estimated MOIC</span><span class="ssv hi">~1.7 to 2.0×</span></div>
          <div class="ss2"><span class="ssl">Estimated IRR</span><span class="ssv">~25 to 35%</span></div>
        </div>
      </div>
      <div class="sc bull">
        <div class="sch"><h3>Bull Case</h3><span class="sct">22× RRD EBITDA</span></div>
        <div class="scb">
          <div class="ss2"><span class="ssl">RRD Exit Multiple</span><span class="ssv">22× EBITDA</span></div>
          <div class="ss2"><span class="ssl">RRD Proceeds</span><span class="ssv">~€9.6bn</span></div>
          <div class="ss2"><span class="ssl">SPC Value</span><span class="ssv">~€5.4bn</span></div>
          <div class="ss2"><span class="ssl">SOTP Value</span><span class="ssv">~€15.0bn</span></div>
          <div class="ss2"><span class="ssl">Estimated MOIC</span><span class="ssv hi" style="font-size:18px;">~2.2 to 2.6×</span></div>
          <div class="ss2"><span class="ssl">Estimated IRR</span><span class="ssv" style="color:var(--green);font-weight:600;">~35 to 45%</span></div>
        </div>
      </div>
    </div>
    <div class="cc mt28">
      <div class="ct">IRR Sensitivity by Exit Multiple and Hold Period</div>
      <div class="cs">Illustrative IRR (%) across exit scenarios · Base case at 18× highlighted in navy</div>
      <div class="cw" style="height:260px;"><canvas id="irrChart" role="img" aria-label="IRR sensitivity across exit multiples and hold periods"></canvas></div>
      <div class="leg mt16">
        <span style="display:flex;align-items:center;gap:6px;"><span class="ld" style="background:#243F78;"></span>2 Year Hold</span>
        <span style="display:flex;align-items:center;gap:6px;"><span class="ld" style="background:#0D1B3E;"></span>3 Year Hold</span>
        <span style="display:flex;align-items:center;gap:6px;"><span class="ld" style="background:#B8964E;"></span>4 Year Hold</span>
      </div>
    </div>
    <p class="rd mt16">All return scenarios are illustrative and based on simplified assumptions. They do not account for taxes, transaction costs, debt amortisation schedules or working capital movements. Actual returns will differ materially.</p>
  </div>
</div>

<!-- RISKS -->
<div class="panel" id="p-risks">
  <div class="pi">
    <div class="ey">Risk Factors</div>
    <h2 class="st">Key Risks and Mitigants</h2>
    <div class="dv"></div>
    <p class="ss">A summary of the principal risks associated with this co-investment. Each risk is assessed for severity and accompanied by the primary mitigating factors available to the sponsor and co-investors.</p>
    <div class="rg">
      <div class="rc high"><div class="rh"><div class="rt">Leverage and Interest Rate Risk</div><span class="rl rhi">High</span></div><div class="rdesc">Entry leverage of 7.0 to 7.5 times EBITDA is at the upper end of comparable healthcare LBOs. Rising rates could compress refinancing options and increase the debt service burden over time.</div><div class="rmit">Mitigant: Specialty pharma free cash flow of €559M per year fully covers debt service. CVC has pre-placed debt with committed lenders and rate hedging strategies are in place.</div></div>
      <div class="rc med"><div class="rh"><div class="rt">Regulatory and Pricing Risk</div><span class="rl rme">Medium</span></div><div class="rdesc">EU health technology assessment regulation and national reimbursement decisions could compress rare disease drug pricing, particularly for Isturisa in Germany and France.</div><div class="rmit">Mitigant: Rare disease drug designation and unmet medical need create strong pricing protection. Revenue is diversified across 11 drugs with no single product exceeding 50% of rare disease divisional revenue.</div></div>
      <div class="rc med"><div class="rh"><div class="rt">Patent Cliff and Generic Competition</div><span class="rl rme">Medium</span></div><div class="rdesc">The specialty pharma division is exposed to generic competition as patents expire over the 2026 to 2030 hold period, which could reduce free cash flow generation.</div><div class="rmit">Mitigant: The specialty pharma division is valued at 9 to 11 times EBITDA, already reflecting this risk. Generic pressure accelerates rather than delays the case for an early rare disease division exit.</div></div>
      <div class="rc med"><div class="rh"><div class="rt">Carve-out Execution Risk</div><span class="rl rme">Medium</span></div><div class="rdesc">Separating the rare disease and specialty pharma businesses requires legal, operational and financial disentanglement, with regulatory approvals needed across multiple jurisdictions.</div><div class="rmit">Mitigant: CVC has completed more than 25 corporate carve-outs. The rare disease division already operates with a separate management team, a dedicated logistics hub in Nanterre and standalone financial reporting.</div></div>
      <div class="rc med"><div class="rh"><div class="rt">Italian Political Sensitivity</div><span class="rl rme">Medium</span></div><div class="rdesc">Recordati is a nationally significant Italian listed company. A foreign-led take-private could attract political scrutiny or a golden share review from Italian authorities.</div><div class="rmit">Mitigant: CVC has owned Recordati since 2018 without any political friction. The Italian management team is fully retained and domestic operations, employment and manufacturing are unaffected.</div></div>
      <div class="rc low"><div class="rh"><div class="rt">Isturisa Commercial Execution</div><span class="rl rlo">Lower</span></div><div class="rdesc">Isturisa is the lead rare disease drug asset and the primary driver of the division's exit valuation. A commercial shortfall would compress the exit multiple for the rare disease division materially.</div><div class="rmit">Mitigant: The FDA label was expanded in April 2025 to cover all Cushing's Syndrome patients. Peak sales guidance was revised upward to above €1.2bn. First half 2025 performance shows strong commercial momentum.</div></div>
    </div>
  </div>
</div>

</div>

<footer>
  <div class="fb">Recordati <span>S.p.A.</span> · Co-Investment</div>
  <div class="fd">This document is confidential and has been prepared for sophisticated institutional investors only. It contains illustrative financial scenarios and does not constitute an offer, solicitation or investment advice. Past performance is not indicative of future results. All figures as of 10th April 2026.</div>
</footer>

<script>
Chart.defaults.font.family="'DM Sans',sans-serif";
Chart.defaults.font.size=12;
Chart.defaults.color='#6C6C64';
const N='#0D1B3E',NM='#1A2F5A',NL='#243F78',G='#B8964E',GR='#A8A89E',GL='#E2E2DE',GRN='#1B5E42';
const C={};

function initCharts(id){
  if(id==='financials'&&!C.rev){
    C.rev=new Chart(document.getElementById('revChart'),{type:'bar',data:{labels:['FY2021','FY2022','FY2023','FY2024','FY2025'],datasets:[{label:'Rare Disease',data:[503,692,840,879,1141],backgroundColor:N,borderWidth:0},{label:'Specialty Pharma',data:[980,1080,1190,1449,1478],backgroundColor:G,borderWidth:0}]},options:{responsive:true,maintainAspectRatio:false,plugins:{legend:{display:false},tooltip:{callbacks:{label:c=>` ${c.dataset.label}: €${c.raw}M`}}},scales:{x:{stacked:true,grid:{display:false}},y:{stacked:true,grid:{color:GL},ticks:{callback:v=>`€${v}M`}}}}});
    C.ebitda=new Chart(document.getElementById('ebitdaChart'),{type:'bar',data:{labels:['FY2021','FY2022','FY2023','FY2024','FY2025'],datasets:[{label:'EBITDA (€M)',data:[545,644,727,866,991],backgroundColor:N,borderWidth:0,yAxisID:'y',order:2},{label:'Margin (%)',data:[36.7,36.9,37.1,37.5,37.8],type:'line',borderColor:G,backgroundColor:'transparent',pointBackgroundColor:G,borderWidth:2,pointRadius:4,yAxisID:'y1',order:1}]},options:{responsive:true,maintainAspectRatio:false,plugins:{legend:{display:false}},scales:{x:{grid:{display:false}},y:{grid:{color:GL},ticks:{callback:v=>`€${v}M`},min:0,max:1200},y1:{position:'right',grid:{display:false},ticks:{callback:v=>`${v}%`},min:34,max:42}}}});
  }
  if(id==='captable'&&!C.cap){
    const cd={labels:['CVC Capital Partners','Free Float','PSP Investments','StepStone Group','AlpInvest Partners'],values:[31.5,53.2,6.0,5.5,3.8],colors:[N,'#E2E2DE',NM,NL,'#4A6FA5']};
    C.cap=new Chart(document.getElementById('capChart'),{type:'doughnut',data:{labels:cd.labels,datasets:[{data:cd.values,backgroundColor:cd.colors,borderWidth:2,borderColor:'#fff',hoverOffset:6}]},options:{responsive:true,maintainAspectRatio:false,cutout:'62%',plugins:{legend:{display:false},tooltip:{callbacks:{label:c=>` ${c.label}: ${c.raw}%`}}}}});
    const leg=document.getElementById('capLeg');
    cd.labels.forEach((l,i)=>{leg.innerHTML+=`<div style="display:flex;align-items:center;gap:10px;font-size:13px;"><span style="width:10px;height:10px;border-radius:50%;background:${cd.colors[i]};flex-shrink:0;"></span><span style="flex:1;color:#3A3A34;">${l}</span><span style="font-weight:500;color:#0D1B3E;">${cd.values[i]}%</span></div>`;});
  }
  if(id==='deal'&&!C.sotp){
    C.sotp=new Chart(document.getElementById('sotpChart'),{type:'bar',data:{labels:['Entry EV','RRD Value (18×)','SPC Value (10×)','SOTP Total','Value Gap'],datasets:[{data:[10.11,7.8,4.8,12.6,2.49],backgroundColor:[GR,N,G,GRN,'#C0392B'],borderWidth:0,borderRadius:3}]},options:{responsive:true,maintainAspectRatio:false,plugins:{legend:{display:false},tooltip:{callbacks:{label:c=>` €${c.raw}bn`}}},scales:{x:{grid:{display:false}},y:{grid:{color:GL},ticks:{callback:v=>`€${v}bn`},min:0,max:16}}}});
  }
  if(id==='market'&&!C.mkt){
    const yrs=['2023','2024','2025E','2026E','2027E','2028E','2029E','2030E','2031E','2032E','2033E'];
    const md=yrs.map((_,i)=>parseFloat((135.9*Math.pow(1.138,i)).toFixed(1)));
    md[0]=135.9;md[1]=154.6;
    C.mkt=new Chart(document.getElementById('marketChart'),{type:'line',data:{labels:yrs,datasets:[{data:md,borderColor:N,backgroundColor:'rgba(13,27,62,.07)',fill:true,borderWidth:2,pointBackgroundColor:N,pointRadius:4,tension:0.3}]},options:{responsive:true,maintainAspectRatio:false,plugins:{legend:{display:false},tooltip:{callbacks:{label:c=>` $${c.raw}bn`}}},scales:{x:{grid:{display:false}},y:{grid:{color:GL},ticks:{callback:v=>`$${v}bn`}}}}});
  }
  if(id==='returns'&&!C.irr){
    C.irr=new Chart(document.getElementById('irrChart'),{type:'bar',data:{labels:['Bear 15× RRD','Base 18× RRD','Bull 22× RRD'],datasets:[{label:'2 Year Hold',data:[22,35,47],backgroundColor:NL,borderWidth:0,borderRadius:3},{label:'3 Year Hold',data:[17,28,40],backgroundColor:N,borderWidth:0,borderRadius:3},{label:'4 Year Hold',data:[13,22,33],backgroundColor:G,borderWidth:0,borderRadius:3}]},options:{responsive:true,maintainAspectRatio:false,plugins:{legend:{display:false},tooltip:{callbacks:{label:c=>` ${c.dataset.label}: ~${c.raw}% IRR`}}},scales:{x:{grid:{display:false}},y:{grid:{color:GL},ticks:{callback:v=>`${v}%`},min:0,max:55}}}});
  }
}

document.querySelectorAll('.tb').forEach(btn=>{
  btn.addEventListener('click',()=>{
    const id=btn.dataset.tab;
    document.querySelectorAll('.tb').forEach(b=>b.classList.toggle('on',b.dataset.tab===id));
    document.querySelectorAll('.panel').forEach(p=>p.classList.toggle('on',p.id==='p-'+id));
    window.scrollTo({top:0,behavior:'instant'});
    initCharts(id);
  });
});
</script>
</body>
</html>
